Patient stratification using point of care biomarkers in dry eye disease
暂无分享,去创建一个
[1] R. Shetty,et al. Clinical and Molecular Outcomes After Combined Intense Pulsed Light Therapy With Low-Level Light Therapy in Recalcitrant Evaporative Dry Eye Disease With Meibomian Gland Dysfunction , 2021, Cornea.
[2] S. Chauhan,et al. A new non-human primate model of desiccating stress-induced dry eye disease , 2021, Scientific Reports.
[3] A. Acera,et al. Quantification of a panel for dry-eye protein biomarkers in tears: A comparative pilot study using standard ELISA and customized microarrays , 2021, Molecular vision.
[4] R. Shetty,et al. Tear Fluid Angiogenic Factors: Potential Noninvasive Biomarkers for Retinopathy of Prematurity Screening in Preterm Infants , 2021, Investigative ophthalmology & visual science.
[5] Krati Gupta,et al. Algorithmic approach to diagnosis and management of post-refractive surgery dry eye disease. , 2020, Indian journal of ophthalmology.
[6] R. Mohan,et al. Identification of novel predictive factors for post surgical corneal haze , 2019, Scientific Reports.
[7] R. Shetty,et al. Trehalose augments autophagy to mitigate stress induced inflammation in human corneal cells. , 2019, The ocular surface.
[8] L. Tong,et al. Role of tear film biomarkers in the diagnosis and management of dry eye disease , 2019, Taiwan journal of ophthalmology.
[9] C. Jayadev,et al. Altered tear inflammatory profile in Indian keratoconus patients - The 2015 Col Rangachari Award paper , 2017, Indian journal of ophthalmology.
[10] P. Tu,et al. Analysis of Cytokine Levels in Tears and Clinical Correlations After Intense Pulsed Light Treating Meibomian Gland Dysfunction. , 2017, American journal of ophthalmology.
[11] P. Asbell,et al. TFOS DEWS II Clinical Trial Design Report. , 2017, The ocular surface.
[12] S. Stinnett,et al. Effect of thermal pulsation treatment on tear film parameters in dry eye disease patients , 2017, Clinical ophthalmology.
[13] P. Asbell,et al. The Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical Research , 2017, Investigative ophthalmology & visual science.
[14] S. Pflugfelder,et al. Matrix metalloproteinase-9 in the pathophysiology and diagnosis of dry eye syndrome , 2017 .
[15] J. Mehta,et al. Advances and Clinical Applications of Anterior Segment Imaging Techniques , 2016, Journal of ophthalmology.
[16] A. Kampik,et al. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay. , 2016, Ophthalmology.
[17] D. Paton. Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease. , 2016, Drugs of today.
[18] A. Galor,et al. The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye. , 2016, The ocular surface.
[19] R. Beuerman,et al. Elevated expression of matrix metalloproteinase-9 and inflammatory cytokines in keratoconus patients is inhibited by cyclosporine A. , 2015, Investigative ophthalmology & visual science.
[20] E. Messmer. The pathophysiology, diagnosis, and treatment of dry eye disease. , 2015, Deutsches Arzteblatt international.
[21] S. Tauber,et al. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. , 2013, JAMA ophthalmology.